Conbercept Lowers Recurrence Rates in Patients with Retinopathy of Prematurity

In patients with retinopathy of prematurity (ROP), treatment with conbercept resulted in less recurrence and longer treatment intervals compared with treatment with ranibizumab, according to a study published in

In this retrospective study, 625 patients treated for ROP with either intravitreal conbercept (n = 283 eyes) or ranibizumab (n = 916 eyes) who were followed for ≥12 months were included.

In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09% and the recurrence interval was 7.87 ± 0.65 weeks in the group treated with ranibizumab and 28.57% and 10.6 ± 1.53 weeks, respectively, in the group treated with conbercept.

Recurrence was significantly higher in patients treated with ranibizumab in Zone I ROP and APROP (P = 0.006) and Zone II ROP (P < 0.001) compared with those treated with conbercept. The time to recurrence was significantly longer in patients treated with conbercept compared to those treated with ranibizumab (P < 0.001). No significant difference in the rate of retinal vascularization was reported (P = 0.441).

Reference

Cheng Y, Zhu X, Linghu D, et al. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol. 2020;doi.org/10.1111/aos.14460